FGF19 and portal hypertension: BAs significantly increased in patients stratified by portal hypertension severity (HVPG 6–15 mmHg: 8.98 [5.20–19.4]; HVPG ≥ 16 mmHg: 40.1 [21.5–70.4]; p < 0.001) and disease stage (cACLD: 7.55 [3.38–18.6]; dACLD: 33.5 [15.4–71.4]; p < 0.001), while FGF19 levels tended to increase in patients with dACLD (cACLD: 133 [67.3–222]; dACLD: 157 [114–270]; p = 0.084) but were comparable in patients stratified by HVPG (p = 0.195) (Fig. 1B; Supplementary figure S3).